Yun Zhong
Stock Analyst at Wedbush
(3.96)
# 541
Out of 5,152 analysts
48
Total ratings
56.1%
Success rate
10.92%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yun Zhong
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNKD MannKind | Maintains: Outperform | $10 → $8 | $2.83 | +182.69% | 1 | Mar 5, 2026 | |
| ASND Ascendis Pharma | Maintains: Outperform | $240 → $273 | $237.35 | +15.02% | 4 | Feb 12, 2026 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $32 → $34 | $16.23 | +109.49% | 13 | Jan 23, 2026 | |
| RZLT Rezolute | Maintains: Neutral | $1 → $2 | $3.13 | -36.10% | 2 | Jan 8, 2026 | |
| WVE Wave Life Sciences | Maintains: Outperform | $20 → $33 | $13.20 | +150.00% | 3 | Dec 12, 2025 | |
| KROS Keros Therapeutics | Maintains: Neutral | $15 → $16 | $11.71 | +36.64% | 3 | Nov 6, 2025 | |
| IRD Opus Genetics | Initiates: Outperform | $8 | $4.77 | +67.71% | 1 | Oct 29, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Outperform | $70 → $86 | $91.41 | -5.92% | 3 | Oct 28, 2025 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Outperform | $80 → $18 | $18.02 | -0.11% | 2 | Sep 30, 2025 | |
| PASG Passage Bio | Maintains: Outperform | $3 → $40 | $8.12 | +392.61% | 3 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $5.45 | +413.76% | 1 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $8 | $3.93 | +103.56% | 2 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8 | $4.59 | +74.29% | 1 | May 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $32 | $4.64 | +589.66% | 2 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $28 | $4.76 | +488.24% | 2 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.49 | - | 2 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $16 | $14.33 | +11.65% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $46 | $10.65 | +331.92% | 1 | Jun 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $0.39 | +2,457.54% | 1 | May 5, 2021 |
MannKind
Mar 5, 2026
Maintains: Outperform
Price Target: $10 → $8
Current: $2.83
Upside: +182.69%
Ascendis Pharma
Feb 12, 2026
Maintains: Outperform
Price Target: $240 → $273
Current: $237.35
Upside: +15.02%
Sarepta Therapeutics
Jan 23, 2026
Maintains: Outperform
Price Target: $32 → $34
Current: $16.23
Upside: +109.49%
Rezolute
Jan 8, 2026
Maintains: Neutral
Price Target: $1 → $2
Current: $3.13
Upside: -36.10%
Wave Life Sciences
Dec 12, 2025
Maintains: Outperform
Price Target: $20 → $33
Current: $13.20
Upside: +150.00%
Keros Therapeutics
Nov 6, 2025
Maintains: Neutral
Price Target: $15 → $16
Current: $11.71
Upside: +36.64%
Opus Genetics
Oct 29, 2025
Initiates: Outperform
Price Target: $8
Current: $4.77
Upside: +67.71%
Protagonist Therapeutics
Oct 28, 2025
Maintains: Outperform
Price Target: $70 → $86
Current: $91.41
Upside: -5.92%
MoonLake Immunotherapeutics
Sep 30, 2025
Maintains: Outperform
Price Target: $80 → $18
Current: $18.02
Upside: -0.11%
Passage Bio
Aug 13, 2025
Maintains: Outperform
Price Target: $3 → $40
Current: $8.12
Upside: +392.61%
Aug 11, 2025
Initiates: Outperform
Price Target: $28
Current: $5.45
Upside: +413.76%
Aug 7, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $3.93
Upside: +103.56%
May 27, 2025
Initiates: Outperform
Price Target: $8
Current: $4.59
Upside: +74.29%
May 16, 2025
Reiterates: Outperform
Price Target: $32
Current: $4.64
Upside: +589.66%
Feb 9, 2023
Maintains: Buy
Price Target: $35 → $28
Current: $4.76
Upside: +488.24%
Feb 2, 2023
Downgrades: Neutral
Price Target: n/a
Current: $4.49
Upside: -
Jan 18, 2023
Maintains: Buy
Price Target: $14 → $16
Current: $14.33
Upside: +11.65%
Jun 15, 2021
Initiates: Buy
Price Target: $46
Current: $10.65
Upside: +331.92%
May 5, 2021
Initiates: Buy
Price Target: $10
Current: $0.39
Upside: +2,457.54%